Skip to main content
Pfizer's breast cancer drug approved in EU

Pfizer's Talzenna, or talazoparib, has been approved by the European Commission as a treatment for advanced-stage breast cancer patients with inherited BRCA gene mutation. The decision was backed by data from a late-stage trial in which patients who were treated with Talzenna had their disease progression slow by 46% versus chemotherapy.

Full Story: